Search Results
Aug 27, 2026, 02:00 ET AbbVie Submits Regulatory Application to EMA for SKYRIZI® (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease
children and adolescents from the age of 6 years who are candidates for systemic therapy.Skyrizi, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more
More news about: AbbVie
Aug 06, 2026, 07:00 ET Mediar Therapeutics Enters into a Collaboration and Option Agreement with Ono Pharma to Develop Novel Treatments for Fibro-inflammatory Diseases
targeting fibrotic disorders including, MTX-474, an EphrinB2-targeting antibody in Phase 2 development for systemic sclerosis, MTX-463, an anti-WISP1 antibody in Phase 2 development for idiopathic pulmonary fibrosis in collaboration with Eli Lilly and Company and MTX-439, an anti-SMOC2 antibody in Phase 1
More news about: Mediar Therapeutics
Jul 17, 2026, 07:00 ET DIMERIX EXPANDS PIPELINE WITH ACQUISITION OF PHASE 2 READY ASSET FOR ACUTE KIDNEY INJURY
therapeutics which promote the removal of dysfunctional mitochondria, promoting cell health and function. Mission is currently developing small molecule drug, MTX325 (targeting the CNS) which, through inhibition of the mitochondrial DUB enzyme USP30, promotes clearance of dysfunctional mitochondria – consequently
More news about: Dimerix Limited
Jun 23, 2026, 07:00 ET Mediar Therapeutics Announces First Cohorts Dosed in Phase 1 Clinical Trial of MTX-439 for Fibrosis Associated with Chronic Kidney Disease (CKD) and Additions to Clinical Advisory Board
enables us to advance MTX-439 into later stage development with important rigor and a patient-centric focus."In addition to MTX-439, Mediar is advancing two other novel anti-fibrotics in global Phase 2a studies: MTX-474, an anti-EphrinB2 antibody in development for SSc and MTX-463, a WISP1-targeting
More news about: Mediar Therapeutics
Jun 23, 2026, 03:00 ET AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
children and adolescents from the age of 6 years who are candidates for systemic therapy.Skyrizi, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more
More news about: AbbVie
Jun 23, 2026, 03:00 ET AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
children and adolescents from the age of 6 years who are candidates for systemic therapy.Skyrizi, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more
More news about: AbbVie
Jun 19, 2026, 09:00 ET Fapon Biopharma and MOTE Therapeutics to Present Dual-Platform B-Cell Immunotherapy Franchise at BIO 2026
depletion: FPE024, a potential best-in-class CD19×BCMA×CD3 tri-specific T-cell engager for autoimmune indications, with IND filing targeted Q1 2027; and MTX001, a CD19×BCMA in vivo CAR-T program powered by the mobilize™ tLNP platform, with an investigator-initiated first-in-human
More news about: Fapon Biopharma
May 19, 2026, 10:00 ET MEKanistic Therapeutics Announces FDA Clearance of IND for MTX-531, Enabling Phase 1 Trial in Advanced Solid Tumors
With the IND now in effect, MEKanistic may proceed with its planned Phase 1 clinical study of MTX-531, subject to standard study start-up activities.MTX-531 is a potential first-in-class small molecule designed to selectively inhibit PI3K and EGFR, two signaling pathways
More news about: MEKanistic Therapeutics, Inc.
Apr 23, 2026, 08:00 ET Mozart Therapeutics Announces Positive Interim Phase 1 Data in Adults with Stage 3 Type I Diabetes
data for their lead program, MTX-101, in development for the treatment of type 1 diabetes (T1D). In a series of presentations at the 21st Immunology of Diabetes Society (IDS) Congress—April 20‒24; Brisbane, Australia—the Company provided a comprehensive update on the MTX-101 program, including results
More news about: Mozart Therapeutics
Feb 11, 2026, 08:00 ET 2025 U.S. Consumer Spending on Video Games Nears Pandemic-Level Peak at $60.7 Billion, Second-Highest on Record
game sales reflects consumer spend across all video game content categories (physical and digital full-game, downloadable content/microtransactions (DLC/MTX), subscription spending across console, cloud, mobile, portable, PC and virtual reality (VR) platforms), as well as video game hardware and video game
More news about: Entertainment Software Association
Feb 03, 2026, 08:42 ET 2025 TAG Analysis Shows Ad Industry Progress in Fighting Fraud, Sharing Threats, and Improving Transparency
without those programs in place.High-value threat intelligence critical for fast-changing threats: TAG's Malvertising Threat Exchange (MTX) increased the sharing of high-value intelligence around adversary tactics, techniques, and procedures by 82% over the prior year, strengthening the
More news about: Trustworthy Accountability Group
Jan 28, 2026, 17:31 ET DUB Inhibitors Market to Witness Strong Expansion Across 7MM by 2040 Driven by the Launch of Novel Therapeutics | DelveInsight
OAT-4828 (Molecure), KSQ-4279 (KSQ Therapeutics/Roche), MTX652 and MTX325 (Mission Therapeutics), sepantronium bromide/PC-002/YM155 (Cothera Bioscience), and others.Mission Therapeutics' MTX652 is a potent, highly selective investigational therapy currently in Phase
More news about: DelveInsight Business Research, LLP
Jan 07, 2026, 07:00 ET Mediar Therapeutics Announces Oversubscribed $76 Million Series B Financing and Clinical Advancement of First-in-Class Fibrosis Portfolio
and ICGMTX-474 Global Phase 2a study Initiated in Systemic Sclerosis (SSc)MTX-463 Global Phase 2a Study in Idiopathic Pulmonary Fibrosis (IPF) Enrolling & Partnered with LillyMTX-439 Advancing to Phase 1 studies for
More news about: Mediar Therapeutics
Dec 08, 2025, 19:00 ET Innovent Announces PECONDLE® (Picankibart Injection) Phase 3 Study (CLEAR-2) Meets Endpoints, Delivering Superior Long-Term Management Solution for Moderate-to-Severe Psoriasis
Global psoriasis prevalence varies significantly, with over 7 million patients in China alone. Current systemic treatments in China include methotrexate (MTX), cyclosporine A, retinoic acids, small molecule target agents and biological agents. Since 2019, biologics have become a central focus in psoriasis
More news about: Innovent Biologics
Nov 28, 2025, 04:06 ET China's First Domestic IL-23p19 Monoclonal Antibody: Innovent's PECONDLE® (Picankibart Injection) Received NMPA Approval
Global psoriasis prevalence varies significantly, with over 7 million patients in China alone. Current systemic treatments in China include methotrexate (MTX), cyclosporine A, retinoic acids and biological agents. Since 2019, biologics have become a central focus in psoriasis treatment in China, with IL-23
More news about: Innovent Biologics
Nov 04, 2025, 05:50 ET MTX Group Anuncia Expansão Estratégica para o Brasil, Fortalecendo Presença Global em Transformação Digital
MTX LATAM, braço regional da MTX Group, dos Estados Unidos, e parceira líder em transformação digital e implementação de SaaS, anunciou hoje sua expansão oficial para o Brasil, marcando a entrada do grupo em seu oitavo mercado global. Essa medida estratégica reforça o compromisso da MTX em capacitar
More news about: MTX BRASIL
Oct 22, 2025, 13:51 ET MTX Group Inc. Acquires VerifyID.ai to Advance AI-Powered Digital Identity Verification in the Public Sector
About MTX Group Inc. MTX is a global technology consulting firm that serves as a trusted advisor for government agencies and businesses to modernize through digital transformation. With data as the new currency, MTX helps transform long-term strategy
More news about: MTX Group
Oct 20, 2025, 18:13 ET MTX Group Launches MTX Ventures to Empower Founders Driving the Future of Enterprise AI
realities." MTX Ventures operates as a wholly owned subsidiary of MTX Group, headquartered in Frisco, Texas, and represents a long-term strategic commitment to innovation, collaboration, and social impact across the global AI ecosystem. Through MTX Ventures, MTX Group continues to advance
More news about: MTX Group
Oct 20, 2025, 08:00 ET RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF Inhibitor
blinded extension period (Period 2). Participants were randomized 1:1 to receive upadacitinib (15 mg once daily orally) + MTX versus adalimumab (40 mg subcutaneously every other week) + MTX. Eligible patients continue to receive the same study treatment in Period 2 as assigned in Period 1, up to 48 weeks.
More news about: AbbVie
Oct 15, 2025, 03:30 ET Mission Therapeutics raises $13.3 million to progress first-in-class Parkinson's disease candidate MTX325 through clinical trials
the full execution of Phase Ib proof-of-mechanism study of MTX325 in patients with Parkinson's disease (PD) Comes after successful completion of Phase 1a studies of MTX325, a first-in-class and potentially disease-modifying treatment
More news about: Mission Therapeutics
Sep 22, 2025, 11:30 ET Lab Automation Market is Projected To Reach US$8.71 Billion By 2031 at CAGR of 6.3% | The Insight Partners
mass spectrometry (ICP-MS). The launch includes a new single quadrupole Thermo Scientific iCAP MSX ICP-MS and triple quadrupole Thermo Scientific iCAP MTX ICP-MS designed for environmental, food, industrial and research labs to analyze routine and challenging trace elements to detect and mitigate harmful
More news about: The Insight Partners